DeepMed Research

The New York State Psychiatric Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1895-01-01

Employees: 251

Market Cap: -

Website: http://www.nyspi.org

Clinical Trials

Treatment of Psychosis and Agitation in Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer's Disease
Psychosis
Agitation

Interventions: Drug: Lithium
Drug: Placebo

First Posted Date: 2014-05-02

Last Posted Date: 2024-05-02

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 77

Registration Number: NCT02129348

Locations: 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
New York State Psychiatric Institute, New York, New York, United States
🇺🇸
University of Miami Miller School of Medicine, Miami, Florida, United States

and more 1 locations

Dyadic Therapy for Mothers and Children

Phase 1

Terminated

Conditions: Depression
Behavioral Problems

Interventions: Behavioral: Control (usual treatment)
Behavioral: Child Parent Psychotherapy (CPP)

First Posted Date: 2014-04-25

Last Posted Date: 2017-08-22

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 2

Registration Number: NCT02123160

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Social Circumstances, Parenting Techniques, and Infant Development

Not Applicable

Completed

Conditions: Postpartum Depression
Infant Development
Rhythm; Sleep

Interventions: Behavioral: Resources for Postpartum Parenting

First Posted Date: 2014-04-23

Last Posted Date: 2020-01-28

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 60

Registration Number: NCT02121496

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

Study of Long-Acting Injectable Naltrexone to Treat Cannabis Dependence

Phase 1

Completed

Conditions: Cannabis Dependence

Interventions: Drug: Long-acting injectable naltrexone

First Posted Date: 2014-03-14

Last Posted Date: 2019-04-24

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 12

Registration Number: NCT02088177

Locations: 🇺🇸
STARS clinic, Columbia-New York Presbyterian and New York State Psychiatric Institute, New York, New York, United States
🇺🇸
STARS Downtown, Columbia-Presbyterian and New York State Psychiatric Institute, New York, New York, United States

Developing New Clinical Management Strategies

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo
Drug: Escitalopram

First Posted Date: 2014-03-10

Last Posted Date: 2020-03-03

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 3

Registration Number: NCT02082392

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Depakote (Divalproex Sodium) for Children With Temper Dysregulation and Severe Mood Swings

Phase 4

Completed

Conditions: Irritable Aggression

Interventions: Drug: Divalproex

First Posted Date: 2014-03-05

Last Posted Date: 2017-01-04

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 15

Registration Number: NCT02078596

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Extending Ketamine's Effects in OCD With Exposure and Response Prevention (EX/RP)

Phase 2

Completed

Conditions: Obsessive-Compulsive Disorder

Interventions: Drug: Ketamine
Behavioral: Exposure and Response Prevention

First Posted Date: 2014-02-14

Last Posted Date: 2016-12-29

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 10

Registration Number: NCT02062658

Locations: 🇺🇸
New York State Psychiatric Insitute, New York, New York, United States

Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder

Phase 4

Completed

Conditions: Intermittent Explosive Disorder
Childhood Aggression
Oppositional Defiant Disorder
Attention Deficit Disorder

Interventions: Behavioral: Parent Management Training
Other: Placebo
Drug: Intuniv

First Posted Date: 2014-01-29

Last Posted Date: 2018-06-13

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 11

Registration Number: NCT02048241

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia
Schizoaffective Disorder

Interventions: Drug: Tocilizumab
Drug: Placebo

First Posted Date: 2014-01-13

Last Posted Date: 2018-12-26

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 59

Registration Number: NCT02034474

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Imaging Dopamine Release in Depression

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Pramipexole

First Posted Date: 2014-01-10

Last Posted Date: 2019-11-01

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 52

Registration Number: NCT02033369

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy